ew research integrates sophisticated interdisciplinary approaches to solve a molecular mystery that may lead to alternative therapeutic strategies for acute myeloid leukemia (AML). The study, published by Cell Press in the October issue of the journal Cancer Cell, identifies a previously unrecognized AML target that responds well to pharmacological inhibition and may be an excellent candidate for use in future clinical trials.
AML is a type of blood cancer that
disrupts normal blood cell production. "Long term survival for patients
with AML remains poor despite dose-intensive chemotherapy regimens,"
explains senior study author, Dr. Kimberly Stegmaier from Dana-Farber
Cancer Institute, Broad Institute of Harvard and MIT, and Children's
Hospital Boston. "For older adults, long-term survival is dismal, and
many older patients are unable to tolerate standard cytotoxic therapy."
Unfortunately, identification of new treatment strategies has proven
difficult as many potential targets are proteins that do not respond
well to standard pharmacological methods... Read More